Tamoxifen in Duchenne muscular dystrophy – promising first results

Ruegg, Urs

doi:10.1016/j.nmd.2021.09.003

Scientific article

Editorial

English

Tamoxifen in Duchenne muscular dystrophy – promising first results

ContributorsRuegg, Urs

Published inNeuromuscular disorders, vol. 31, no. 9, p. 801-802

Publication date2021-09-09

Abstract

The most common diseases are of polygenic origin. Since early last century, these are being treated with drugs that act downstream of the genetic hurdle. This strategy has saved millions of lives. The advent of genetics revealed the molecular basis of diseases of monogenic origin, including the neuromuscular ones. It was tempting to believe that the defective genes can be repaired with novel chemicals, with a cure being “just down the road”.

Keywords

Duchenne muscular dystrophy
Pharmacology.
Clinical Trial
Tamoxifen
Patients

Affiliation

Faculté des sciences / Section des sciences pharmaceutiques

Research group

Pharmacologie moléculaire

Citation (ISO format)

RUEGG, Urs. Tamoxifen in Duchenne muscular dystrophy – promising first results. In: Neuromuscular disorders, 2021, vol. 31, n° 9, p. 801–802. doi: 10.1016/j.nmd.2021.09.003

Article (Published version)

Identifiers

PID : unige:160704
DOI : 10.1016/j.nmd.2021.09.003

Commercial URLhttps://www.nmd-journal.com/article/S0960-8966(21)00624-6/fulltext

ISSN of the journal0960-8966

65views

0downloads

Creation04/29/2022 8:37:00 AM

First validation04/29/2022 8:37:00 AM

Update time03/16/2023 6:30:31 AM

Status update03/16/2023 6:30:30 AM

Last indexation08/31/2023 8:23:30 AM

Archive ouverte UNIGE

Tamoxifen in Duchenne muscular dystrophy – promising first results

Technical informations